fashion -WSS

fashion

author：Wikipedia 2025-10-01 04:11:39 - browse：5165

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： For Medicare Advantage, Democrats want stronger protections around AI

WSS

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Key House Republican on health care plans exit from Congress

How digital tools helped lower hypertension in marginalized patients

Beam Therapeutics to lay off 20% of its staff, re

Biden report: The neurospychology of memory and aging

Key House Republican on health care plans exit from Congress

Wikipedia

fashion

explore

Duchenne breakthrough therapy leaves behind pioneering families

Pharmacists can make shortage drugs, but at what cost?

Sports medicine is finally prioritizing gender equality

HHS leader on health, climate change and biopharma emissions

After affirmative action ruling, medical educators look to 'holistic review'

Medicare reduced heart disease by changing how it pays doctors

Affirmative action in medical school literally saved lives

Biogen Alzheimer’s drug launch off to slow start

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

explore

Readout LOUD podcast: How biotech is using artificial intelligence

For Medicare Advantage, Democrats want stronger protections around AI

Impact of Dobbs ruling felt at reproductive medicine meeting

Biden report: The neurospychology of memory and aging

Biden report: The neurospychology of memory and aging

STAT Readout Newsletter: Today's biggest biotech updates

focus

focus

hotspot

entertainment